Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.62 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780605 | 0.92 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL14582313 | 0.89 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL1782207 | 0.88 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL5465079 | 0.88 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL14582392 | 0.87 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL14582368 | 0.86 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL14582306 | 0.86 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL14582336 | 0.86 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL14582310 | 0.85 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR | |
| SCHEMBL5462399 | 0.85 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | claimed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| EP-1885701-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | Novartis Vaccines and Diagnostics, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2006113498-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885ADORA2A 3956/4885 |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | HSP90AA1 3373/4885HSP90AB1 3036/4885ADORA2A 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.